41100-45-2 Usage
Description
3-Ethyladamantan-1-amine is an organic compound with a unique adamantane-based structure, featuring an ethyl group and an amine functional group. It is characterized by its rigid and compact molecular architecture, which may contribute to its potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3-Ethyladamantan-1-amine is used as an intermediate compound for the synthesis of various pharmaceuticals. Its adamantane-based structure and amine functionality make it a valuable building block for the development of new drugs with potential applications in treating neurological disorders, such as Parkinson's disease and Alzheimer's disease.
Used in Chemical Synthesis:
3-Ethyladamantan-1-amine can be used as a versatile starting material in the synthesis of a wide range of organic compounds. Its unique structure and functional groups can be further modified or reacted with other molecules to create new compounds with specific properties and applications in various industries, such as materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
Due to its unique structural features, 3-ethyladamantan-1-amine may be employed as a research tool in the study of molecular interactions, conformational analysis, and the development of new synthetic methodologies. It can also be used to investigate the effects of structural modifications on the properties and reactivity of adamantane-based compounds.
Synthesis Reference(s)
Journal of Medicinal Chemistry, 25, p. 51, 1982 DOI: 10.1021/jm00343a010
Check Digit Verification of cas no
The CAS Registry Mumber 41100-45-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,1,0 and 0 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 41100-45:
(7*4)+(6*1)+(5*1)+(4*0)+(3*0)+(2*4)+(1*5)=52
52 % 10 = 2
So 41100-45-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H21N/c1-2-11-4-9-3-10(5-11)7-12(13,6-9)8-11/h9-10H,2-8,13H2,1H3
41100-45-2Relevant articles and documents
PROCESS FOR PRODUCING 3-ETHYL-1-ADAMANTYLAMINE
-
, (2020/10/16)
PROBLEM TO BE SOLVED: To provide an industrially economical and efficient synthetic method of 3-ethyl-1-adamantylamine, which does not include a synthetic process of 1-bromo-3-ethyladamantane which uses harmful halogen and which, in a synthetic reaction of 1-amide-3-ethyladamantane, suppresses by-products and improves a yield by reducing amounts of use of an amide or an acid and a nitrile relative to adamantanes, and also remarkably reduces wastes derived from the amide or the acid and the nitrile. SOLUTION: A method for producing 3-ethyl-1-adamantylamine comprises the following steps (i) to (iii): (i) a step of obtaining a reaction mixture by reacting 3-ethyl-1-adamantanol with an acid and a nitrile in an organic solvent; (ii) a step of obtaining 1-amide-3-ethyladamantane by adding water to the reaction mixture obtained in the step (i); and (iii) a step of hydrolyzing 1-amide-3-ethyladamantane obtained in the step (ii) in the presence of an alcohol-containing solvent and an inorganic base. COPYRIGHT: (C)2015,JPO&INPIT
METHODS OF TREATING CNS DISORDERS
-
, (2009/12/02)
The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
-
, (2008/06/13)
The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine.
